43 filings
Page 2 of 3
8-K
7odgt2x513xl9f1
13 Mar 12
Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial
12:00am
8-K
wzplg9nhe 324v1z5s
26 Jan 12
Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
12:00am
8-K
vqxp l0ypv8523vpcte
25 Jan 12
Other Events
12:00am
8-K
td5xy7va0l5y1ovepgg
23 Jan 12
Other Events
12:00am
8-K
r0i8bj2zl550ncvb7mb
3 Jan 12
Statements made in this presentation regarding matters that are not historical facts are “forward-looking statements” within
12:00am
8-K
vgwji
20 Dec 11
Regulation FD Disclosure
12:00am
8-K
v6vktlo
19 Dec 11
Trius Reports Positive Results from First Phase 3 Trial of
12:00am
8-K
7z0ko
10 Nov 11
Trius Therapeutics Reports 2011 Third Quarter Financial Results
12:00am
8-K
8jzgmtwrfgriokvi sp
17 Aug 11
Departure of Directors or Certain Officers
12:00am
8-K
x58yaljzm6o3mvtj
11 Aug 11
Trius Therapeutics Reports 2011 Second Quarter Financial Results
12:00am
8-K
4x0tkm56v1styta
5 Aug 11
Trius Therapeutics Obtains Special Protocol Assessment with Fda for Second Phase 3 Study of Torezolid Phosphate
12:00am
8-K
lb6kv57u1aqar kyz7
27 Jul 11
Trius Therapeutics and Bayer Form Strategic Collaboration to
12:00am
8-K
pqzvd6gsou qdx
3 Jun 11
Submission of Matters to a Vote of Security Holders
12:00am
8-K
f020 nwf4
25 May 11
Trius Therapeutics Announces Pricing of $30 Million Financing
12:00am
8-K
gimn bhfx3ile8
5 May 11
Trius Therapeutics Reports 2011 First Quarter Financial Results
12:00am
8-K
g35njeofk 0i1
23 Mar 11
Trius Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results
12:00am
8-K
exzhblg b1wzvru
28 Feb 11
Trius Announces Positive Results from Phase 1 Lung Study of
12:00am
8-K
lbfrvi0
12 Nov 10
Trius Therapeutics Reports 2010 Third Quarter Results
12:00am
8-K
g4x6f u7yp
9 Nov 10
Departure of Directors or Certain Officers
12:00am
8-K
ywtk opyi4ovqd4g41
13 Sep 10
Trius Reports New Findings on Mechanisms of Antibiotic Resistance In Mrsa
12:00am